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PARTICIPANTS WHO WOULD BENEFIT: Members
of P&T, MCO and others assessing formulary inclusion
and cost-benefits of asthma therapies. Asthma has in-
creased 10-fold in the last 2 decades, costing $6 B/year in
the US. The most severe asthmatics account for the majority
of the total health care costs, endpoints involving emergency
department treatment ($250) and hospital admission
($3100). Anti-inflammatories (steroids, leukotriene modifi-
ers) are recommended for most levels of asthma severity and
should be able to alter these endpoints. However, initial pre-
scription filling (50–80%) and refilling (20–40%) rates are
so poor as to preclude comparisons of drug effectiveness
or health care plans. While disease management of asthma
would wish to alter these endpoint costs, it is not possible
to develop a PD-PE model to compare effectiveness of
asthma anti-inflammatories across or within plans.
OBJECTIVES: To develop a PD-PE model to compare ef-
fectiveness of anti-inflammatory therapies. To obviate the
above limitations, we used published clinical results in-
volving moderate-severe asthmatics in terms of improved
lung function ((0.1L FEV1) calibrated against the anti-
inflammatory inhaled therapy costs (per-day  treatment
duration). Additional cost reductions related to reduced
need for metered dose inhalers were also tabulated.
RESULTS: These analyses show $US costs to achieve a
0.1L improvement in moderate-severe asthmatics using
steroids such as budesonide ($232) or beclomethasone
($110), leukotriene modifiers (zileuton $68 or montelukast
$101), as well as the single isomer -agonist levalbuterol
($39). Chronic treatment with racemic albuterol did not
improve lung function but rather resulted in a decrease in
lung function. Each final cost is inclusive of reduced al-
buterol metered dose inhaler costs.
CONCLUSIONS: This cross-stratified PD-PE model as-
sessed anti-inflammatory therapy impact on improvements
in asthma lung function and reduced need for rescue MDI.
As these results are derived from well-controlled clinical
studies, they reflect optimized treatment compliance and
therefore maximal PD-PE effect. Accordingly, these rela-
tive scores may provide insights relating to formulary in-
clusion of drugs which face class competition.
ECONOMIC AND OUTCOMES ISSUES OF 
GASTROINTESTINAL DISORDERS
PGI1
EFFECTIVENESS OF OMEPRAZOLE, 
AMOXICILLIN, AND CLARITHROMYCIN IN 
ERADICATING HELICOBACTER PYLORI IN 
PATIENTS ON CHRONIC ACID SUPPRESSION 
FOR PEPTIC ULCER DISEASE OR
ULCER-LIKE SYMPTOMS
Allison J, Hiatt R, Levin TR, Lieu T, Ackerson L, Hurley L, 
Libran D
Kaiser Permanente Division of Research, Oakland, CA, USA
OBJECTIVE: To evaluate the effectiveness of the omepra-
zole, amoxicillin, and clarithromycin (OAC) regimen in
eradicating H. pylori (HP) in patients on long term acid
suppression medicine for documented ulcer or ulcer like
symptoms.
METHODS: Kaiser Permanente data bases were accessed
to identify all patients receiving acid suppression therapy
for at least three 30-day periods within the most recent 12-
month time frame. Those identified were then matched to
databases that capture physician recorded diagnoses at
each patient visit. Patients not previously treated for HP
and with documented (by endoscopy or UGI) diagnoses of
duodenal ulcer (DU), gastric ulcer (GU), gastritis, and un-
specified peptic ulcer disease (PUD) or ulcer like symptoms
were selected for recruitment. Study participants were ran-
domly assigned to C14 urea breath testing (UBT) and HP
eradication, if positive, versus standard maintenance acid
suppressive therapy. All patients positive on UBT (except
those allergic to penicillin N  12) were treated with ome-
prazole 20 mg, amoxicillin 1gm, clarithromycin 500 mg
bid for 10 days. Proof of eradication was documented by
UBT administered 4 weeks post treatment. Each patient
testing negative after treatment was taken off acid reduc-
ing medication and followed for up to one year.
RESULTS: Ninety-five of 96 patients completed 10 days
of OAC, and 89 have been retested 4 weeks later. Of those
retested, 85% (95% CI  76%, 92%) were breath test
negative and 15% (95% CI  8%, 24%) were breath test
positive. Fourteen participants reported recurrent symp-
toms following HP eradication. Side effects of patients on
the regimen were reported by 6 out of 96 treated (6%),
and included bloody diarrhea (1), rash (4), and abdominal
cramps (2).
CONCLUSION: OAC is an effective regimen for eradicat-
ing HP in infected patients on chronic acid suppression for
PUD or ulcer like symptoms. Compliance with the regi-
men is high and serious adverse reactions are low.
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DIAGNOSIS AND TREATMENT OF 
CONSTIPATION IN A MANAGED
CARE POPULATION
Bramley T1, McLaughlin T2, Margraf T3, Okamoto L2
1University of South Carolina, Columbia, SC, USA; 2NDC 
Health Information Services, Phoenix, AZ, USA; 3Pharmetrics, 
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PURPOSE: To assess the cost of care associated with the
treatment of constipation subjects.
METHODS: All subjects contained within PharMetrics In-
tegrated Outcomes database possessing an ICD-9-CM 
564.0 between January 1, 1996 and March 31, 1998 were
eligible for study inclusion. Subjects were required to have
data available for analysis 6 months preceding and follow-
ing the date of their constipation diagnosis. Charge data
were evaluated over the 6-month intervals surrounding the
index date. Additionally, monthly charges were plotted
over the entire 12-month interval to allow examination of
trends associated with the diagnosis and treatment of con-
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stipation. Comorbidities and drug utilization related to
constipation were also assessed.
RESULTS: 9,301 patients met all inclusion criteria. The
mean age was 39.74 years and 63.41% of the sample was
female. The most commonly observed comorbidities were
hypertension (16.3%), diabetes (7.5%), diverticulitis (7.4%)
and irritable colon (5.9%). Approximately 8% of the sam-
ple received medications thought to have constipating ef-
fects in the 6-month period prior to their constipation
diagnosis. Prescription laxative use was observed in ap-
proximately 3% of subjects after the constipation diagno-
sis. Average costs rose from $277 (SD  1717) 6 months
prior to the constipation diagnosis to $1031 (SD  4402)
during the month of the diagnosis. Similarly, average costs
decreased from $890 (SD  3852) in the month directly
following the index date to $479 (SD  3470) in the sixth
month following the index date.
CONCLUSION: Costs associated with the diagnosis and
treatment of constipation patients appear to be concen-
trated around the index visit. Early detection and resolu-
tion of constipation could result in significant cost savings
for managed care organizations.
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DIFFERENTIAL COST OF USING NSAIDS IN A 
MEDICAID POPULATION
Dickson WM, Reeder CE
College of Pharmacy, University of South Carolina, Columbia, 
SC, USA
OBJECTIVES: To estimate the differential cost of using
non-steroidal anti-inflammatory drugs (NSAIDs) in a
Medicaid population. NSAID use is associated with ad-
verse gastrointestinal (GI) events such as GI distress, symp-
tomatic ulcer, and anemia, which vary in severity and may
require symptomatic treatment or hospitalization. The
economic burden of these events is represented by the dif-
ferential cost of treating NSAID-related toxicities.
METHODS: Treatment cost and adverse GI event rates
were compared for two cohorts (NSAID and non-NSAID
users) selected retrospectively from the South Carolina
Medicaid population. To be included in the analysis, all
subjects must have been at least 18 years old and continu-
ously eligible for 12 months following an index event in
1995. For NSAID users, the index event was at least two
NSAID prescriptions or a 60 day supply (n  21,278). For
non-NSAID users (comparator group), the index event
was at least one prescription during 1995 (n  152,072).
Average cost per subject by type of service (physician,
other ambulatory, inpatient hospital, outpatient hospital,
emergency department, prescription drugs) was compared
for the cohorts. Regression analysis was used to evaluate
the effect of NSAID use on treatment cost, controlling for
age, gender, prior exposure to NSAIDs, use of gastro-pro-
tective agents, and adverse GI events.
RESULTS: NSAID users had higher physician ($1885 vs.
$1488), other ambulatory ($5785 vs. $5060), inpatient
hospital ($5966 vs. $3326) and prescription drug ($1012
vs. $738) costs than the non-NSAID group. Regression
analysis showed that NSAID use was a significant explana-
tory variable (p  0.0001), as were age, gender, race, and
adverse GI events.
CONCLUSIONS: NSAID use is associated with higher av-
erage treatment costs and is a significant predictor of mod-
eled treatment costs after controlling for other effects. Sub-
stantial cost savings may be realized if NSAID-related GI
toxicities and adverse events can be managed or avoided.
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COST OF ITALIAN DYSPEPTIC PATIENTS: 
A FEASIBILITY STUDY FROM THE
DYSPEPSIA PROJECT
Triossi O1, Tampieri I1, Casetti T1, Degli Esposti E2, Buda S3, 
Cuttin S3
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The Dyspepsia Project is a General Practitioners’ (GPs)
project, aiming to establish an epidemiological database in
order to describe and follow up dyspeptic patients in the
Ravenna area.
OBJECTIVE: To investigate the feasibility of a cost of ill-
ness study on the dyspeptic patient in terms of healthcare
resource use, and to produce an average cost per patient.
METHOD: Retrospective cost of illness analysis based on
records of 106 dyspeptic patients followed by 10 GPs.
This preliminary analysis has been performed in the per-
spective of Health System. Patients analyzed were enrolled
between September and December 1999 and followed up
at least for 6 months. Hospital admissions; GP, specialist
and emergency room visits; instrumental and laboratory
tests; drugs were analyzed; each cost variable was valued
in Italian Liras 1999 (1800 ITL  1 US$) using published
regional or national tariffs and marked prices for drugs.
Patients have been divided into Group A (37  35%) and
Group B (69  65%), according to whether they under-
went or not gastroscopy test.
RESULTS: The average cost per patient was ITL
1,121,654 in A Group and ITL 624,565 in B Group. Di-
rect costs accounted for 76.5% of the total value in A
Group and for 70.9% in B Group, while the remaining
23.5% in A Group and 29.1% in B Group was due to in-
direct costs (i.e., productivity losses). In Group A the ma-
jor cost driver was drugs (40.8%) (13.6% was the share of
antidyspeptic drugs) followed by tests (18.4%), visits
(15.6%) and emergency room visits (1.7%); in B Group
the major cost driver was drugs (38.6%) (10.1% was the
share of antidyspeptic drugs) followed by visits (19.5%),
tests (9.2%) and emergency room visits (3.6%).
CONCLUSIONS: Collection of cost data at General Prac-
titioner’s level is very effective as it allows a precise and ap-
propriate analysis.
